Answers are grounded in this paper and cite their sources.
Objective: To investigate the effectiveness and adverse events of mandibular advancement device (MAD) in patients with obstructive sleep apnea (OSA) and to identify predictive clinical parameters for therapy success.Methods: A retrospective analysis of 318 patients indicated for MAD therapy, observed in a large teaching hospital in the Netherlands.Results: Ninety-seven patients (65.5%) achieved therapy success. A significant decrease in AHI (apnea–hypopnea index) and OSA-related symptoms was observed. None of the analyzed OSA-characteristics proved to be a significant predictive parameter for therapy success. Side-effects were reported in 54.4% of the patients, with temporomandibular dysfunction (27.0%) being the most frequent. Seventy-four patients (23.3%) discontinued treatment due to side-effects or therapy failure.Conclusion: MAD proved to be effective in the treatment of OSA and can be a viable alternative to CPAP in patients with severe OSA. Side-effects were relatively common and led to termination of therapy in 1 out of 10 cases.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: